Skip to main content

Select Drug Profiles

Payers' Guide, FDA Approvals

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Payers' Guide, FDA Approvals

Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

FDA Approvals of Novel Brand-Name Prescription Drugs in 2018

Payers' Guide, FDA Approvals

Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma

Payers' Guide, FDA Approvals

Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis

FDA Approvals, Oncology Overview, Payers' Guide, Oncology

New Indications Approved by the FDA in 2018 for Oncology Drugs

Dalia Buffery, MA, ABD

Breast Cancer, FDA Approvals, In the News, Oncology

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, In the News, Oncology

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

Page 56 of 244
Results 551 - 560 of 2434